Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity

Stefan Kiesgen, John C. Messinger, Navin K. Chintala, Zachary Tano, Prasad S. Adusumilli

Published: 2021-02-14 DOI: 10.1038/s41596-020-00467-0

CAR T-cell

cytotoxicity assay

immune effector cells

antitumor efficacy

FDA directives

AI 解读

暂无数据

Author Correction: Full-length sequencing of circular DNA viruses and extrachromosomal circular DNA using CIDER-Seq

Generation of heart-forming organoids from human pluripotent stem cells

Design and fabrication of wearable electronic textiles using twisted fiber-based threads

Activation of mechanoluminescent nanotransducers by focused ultrasound enables light delivery to deep-seated tissue in vivo

Chromatin accessibility profiling by ATAC-seq

Deoxyfluorination of phenols for chemoselective18F-labeling of peptides

Author Correction: cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA

Human primordial germ cell-like cells specified from resetting precursors develop in human hindgut organoids

An inexpensive semi-automated sample processing pipeline for cell-free RNA extraction

Application of CHyMErA Cas9-Cas12a combinatorial genome-editing platform for genetic interaction mapping and gene fragment deletion screening

查看全部

Sections

Figures

References

Matta, H. et al. Development and characterization of a novel luciferase based cytotoxicity assay. Sci. Rep. 8, 199 (2018).
Brown, C. E. et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J. Immunol. Methods 297, 39–52 (2005).
Tyagarajan, S., Spencer, T. & Smith, J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol. Ther. Methods Clin. Dev. 16, 136–144 (2020).
Quah, B. J. & Parish, C. R. The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. J. Vis. Exp. 44, 2259 (2010).
Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82–88 (2019).
Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1–11 (2018).
Slaney, C. Y., Wang, P., Darcy, P. K. & Kershaw, M. H. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 8, 924–934 (2018).
Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498–513 (2018).
Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471–482 (2019).
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
Kiesgen, S., Chicaybam, L., Chintala, N. K. & Adusumilli, P. S. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies. J. Thorac. Oncol. 13, 16–26 (2018).
Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).
Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).
Brunner, K. T., Mauel, J., Cerottini, J. C. & Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14, 181–196 (1968).
Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).
Daher, M. & Rezvani, K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr. Opin. Immunol. 51, 146–153 (2018).
Whiteside, T. L. Measurement of cytotoxic activity of NK/LAK cells. Curr. Protoc. Immunol. Chapter 7, Unit 7 18 (2001).
Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).
Peper, J. K. et al. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J. Immunol. Methods 405, 192–198 (2014).
Karimi, M. A. et al. Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay. PLoS ONE 9, e89357 (2014).
Borella, P., Bargellini, A., Salvioli, S., Medici, C. I. & Cossarizza, A. The use of non-radioactive chromium as an alternative to 51Cr in NK assay. J. Immunol. Methods 186, 101–110 (1995).
Schafer, H., Schafer, A., Kiderlen, A. F., Masihi, K. N. & Burger, R. A highly sensitive cytotoxicity assay based on the release of reporter enzymes, from stably transfected cell lines. J. Immunol. Methods 204, 89–98 (1997).
Thorne, N., Inglese, J. & Auld, D. S. Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem. Biol. 17, 646–657 (2010).
Fu, X. et al. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS ONE 5, e11867 (2010).
Rossignol, A., Bonnaudet, V., Clemenceau, B., Vie, H. & Bretaudeau, L. A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective. mAbs 9, 521–535 (2017).
Hayek, S. et al. Identification of primary natural killer cell modulators by chemical library screening with a luciferase-based functional assay. SLAS Discov. 24, 25–37 (2019).
Omokoko, T. A. et al. Luciferase mRNA transfection of antigen presenting cells permits sensitive nonradioactive measurement of cellular and humoral cytotoxicity. J. Immunol. Res. 2016, 9540975 (2016).
Abassi, Y. A. et al. Label-free, real-time monitoring of IgE-mediated mast cell activation on microelectronic cell sensor arrays. J. Immunol. Methods 292, 195–205 (2004).
Zhu, J., Wang, X., Xu, X. & Abassi, Y. A. Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J. Immunol. Methods 309, 25–33 (2006).
Xi, B. et al. A real-time potency assay for chimeric antigen receptor T cells targeting solid and hematological cancer cells. J. Vis. Exp. 153 (2019).
Kho, D. et al. Application of xCELLigence RTCA biosensor technology for revealing the profile and window of drug responsiveness in real time. Biosensors 5, 199–222 (2015).
Davenport, A. J. et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol. Res. 3, 483–494 (2015).
Martinez-Serra, J. et al. xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies. OncoTargets Ther. 7, 985–994 (2014).
Cerignoli, F. et al. In vitro immunotherapy potency assays using real-time cell analysis. PLoS ONE 13, e0193498 (2018).
Hillger, J. M., Lieuw, W. L., Heitman, L. H. & AP, I. J. Label-free technology and patient cells: from early drug development to precision medicine. Drug. Discov. Today 22, 1808–1815 (2017).
Erskine, C. L., Henle, A. M. & Knutson, K. L. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J. Vis. Exp. 66, e3683 (2012).
Jedema, I., van der Werff, N. M., Barge, R. M., Willemze, R. & Falkenburg, J. H. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103, 2677–2682 (2004).
Riccardi, C. & Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1458–1461 (2006).
Aubry, J. P. et al. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37, 197–204 (1999).
Logue, S. E., Elgendy, M. & Martin, S. J. Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat. Protoc. 4, 1383–1395 (2009).
Jin, Q. et al. Rapid flow cytometry-based assay for the evaluation of gammadelta T cell-mediated cytotoxicity. Mol. Med. Rep. 17, 3555–3562 (2018).
Ozdemir, O., Ravindranath, Y. & Savasan, S. Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexinV/propidium iodide colabeling by fluorosphere-adjusted counts on three-color flow cytometry. Cytometry A 56, 53–60 (2003).
Goldberg, J. E., Sherwood, S. W. & Clayberger, C. A novel method for measuring CTL and NK cell-mediated cytotoxicity using annexin V and two-color flow cytometry. J. Immunol. Methods 224, 1–9 (1999).
Liu, L. et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 8, 185–189 (2002).
Packard, B. Z. & Komoriya, A. Intracellular protease activation in apoptosis and cell-mediated cytotoxicity characterized by cell-permeable fluorogenic protease substrates. Cell Res. 18, 238–247 (2008).
Motzer, S. A., Tsuji, J., Hertig, V., Johnston, S. K. & Scanlan, J. Natural killer cell cytotoxicity: a methods analysis of 51chromium release versus flow cytometry. Biol. Res. Nurs. 5, 142–152 (2003).
Joslin, J. et al. A fully automated high-throughput flow cytometry screening system enabling phenotypic drug discovery. SLAS Discov. 23, 697–707 (2018).
Spitzer, M. H. & Nolan, G. P. Mass cytometry: single cells, many features. Cell 165, 780–791 (2016).
Brummelman, J. et al. Development, application and computational analysis of high-dimensional fluorescent antibody panels for single-cell flow cytometry. Nat. Protoc. 14, 1946–1969 (2019).
Martinez, E. M. et al. High-throughput flow cytometric method for the simultaneous measurement of CAR-T cell characterization and cytotoxicity against solid tumor cell lines. SLAS Discov. 23, 603–612 (2018).
Lichtenfels, R., Biddison, W. E., Schulz, H., Vogt, A. B. & Martin, R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 172, 227–239 (1994).
Rafiq, S. et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen. Leukemia 31, 1788–1797 (2017).
Neri, S., Mariani, E., Meneghetti, A., Cattini, L. & Facchini, A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin. Diagn. Lab. Immunol. 8, 1131–1135 (2001).
Gillissen, M. A. et al. The modified FACS calcein AM retention assay: A high throughput flow cytometer based method to measure cytotoxicity. J. Immunol. Methods 434, 16–23 (2016).
Fassy, J., Tsalkitzi, K., Salavagione, E., Hamouda-Tekaya, N. & Braud, V. M. A real-time digital bio-imaging system to quantify cellular cytotoxicity as an alternative to the standard chromium-51 release assay. Immunology 150, 489–494 (2017).
von Zons, P. et al. Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin. Diagn. Lab. Immunol. 4, 202–207 (1997).
Decker, T. & Lohmann-Matthes, M. L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115, 61–69 (1988).
Janetzki, S. et al. Guidelines for the automated evaluation of Elispot assays. Nat. Protoc. 10, 1098–1115 (2015).
Streeck, H., Frahm, N. & Walker, B. D. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat. Protoc. 4, 461–469 (2009).
Shafer-Weaver, K. et al. The granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Transl. Med. 1, 14 (2003).
Malyguine, A. M., Strobl, S., Dunham, K., Shurin, M. R. & Sayers, T. J. ELISPOT assay for monitoring cytotoxic T lymphocytes (CTL) activity in cancer vaccine clinical trials. Cells 1, 111–126 (2012).
Aktas, E., Kucuksezer, U. C., Bilgic, S., Erten, G. & Deniz, G. Relationship between CD107a expression and cytotoxic activity. Cell. Immunol. 254, 149–154 (2009).
Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15–22 (2004).
Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130–3144 (2016).
Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 6, 133–146 (2016).
Chen, N., Li, X., Chintala, N. K., Tano, Z. E. & Adusumilli, P. S. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr. Opin. Immunol. 51, 103–110 (2018).
Guha, P., Reha, J. & Katz, S. C. Immunosuppression in liver tumors: opening the portal to effective immunotherapy. Cancer Gene Ther. 24, 114–120 (2017).
Tano, Z. et al. MA06. 06 An ex-vivo patient-derived, immunocompetent (PDI) culture system to evaluate immunotherapeutic agents’ anti-tumor efficacy. J. Thorac. Oncol. 13, S376 (2018).
US Food and Drug Administration. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs): Guidance for Industry. https://www.fda.gov/media/113760/download. Accessed 18 September 2020.
US Food and Drug Administration. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). 2008. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-review-chemistry-manufacturing-and-control-cmc-information-human-somatic-cell-therapy. Accessed 18 September 2020.
US Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. 2011. https://www.fda.gov/media/79856/download. Accessed 18 September 2020.
de Wolf, C., van de Bovenkamp, M. & Hoefnagel, M. Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy. Cytotherapy 20, 601–622 (2018).
Kassim, S. Toward an integrated model of product characterization for CAR-T cell therapy drug development efforts. Cell Gene Ther. Insight 3, 227–237 (2017).
Castella, M. et al. Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial. Front. Immunol. 11, 482 (2020).
Jackson, Z. et al. Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma. Front. Immunol. 11, 1941 (2020).
US Food and Drug Administration. Summary Basis for Regulatory Action. BLA 125643. YESCARTA. 2017. https://www.fda.gov/media/108788/download. Accessed 18 September 2020.
US Food and Drug Administration. FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting. BLA 125646: Tisagenlecleucel, Novartis Pharmaceuticals Corporation. https://www.fda.gov/media/106081/download. Accessed 18 September 2020.
Eerola, A. K., Soini, Y. & Paakko, P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6, 1875–1881 (2000).
Steele, K. E. et al. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis. J. Immunother. Cancer 6, 20 (2018).
Hillerdal, V., Nilsson, B., Carlsson, B., Eriksson, F. & Essand, M. T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc. Natl Acad. Sci. USA 109, 15877–15881 (2012).
Tseng, C. T. & Klimpel, G. R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195, 43–49 (2002).
Bhat, R., Dempe, S., Dinsart, C. & Rommelaere, J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int. J. Cancer 128, 908–919 (2011).
Oberg, H. H. et al. Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against pancreatic cancer cells. Cancer Res. 74, 1349–1360 (2014).
Clemenceau, B. et al. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood 107, 4669–4677 (2006).
Kurai, J. et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 13, 1552–1561 (2007).
Joshi, T. et al. The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. PLoS ONE 4, e4208 (2009).
Rigo, V. et al. Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. Sci. Rep. 7, 14049 (2017).
Liu, C. et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109, 4336–4342 (2007).
Chen, X. et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget 7, 27764–27777 (2016).
Nazarian, A. A. et al. Characterization of bispecific T-cell engager (BiTE) antibodies with a high-capacity T-cell dependent cellular cytotoxicity (TDCC) assay. J. Biomol. Screen. 20, 519–527 (2015).
Martin-Manso, G. et al. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 68, 7090–7099 (2008).
Cook, K. L. et al. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin. Cancer Res. 20, 3222–3232 (2014).
El-Andaloussi, N. et al. Generation of an adenovirus–parvovirus chimera with enhanced oncolytic potential. J. Virol. 86, 10418–10431 (2012).
Fajardo, C. A. et al. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 77, 2052–2063 (2017).
Kute, T. E. et al. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol. Immunother. 58, 1887–1896 (2009).
Hermans, I. F. et al. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 285, 25–40 (2004).
Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 66, 10145–10152 (2006).
Kasatori, N., Ishikawa, F., Ueyama, M. & Urayama, T. A differential assay of NK-cell-mediated cytotoxicity in K562 cells revealing three sequential membrane impairment steps using three-color flow-cytometry. J. Immunol. Methods 307, 41–53 (2005).
Hoppner, M., Luhm, J., Schlenke, P., Koritke, P. & Frohn, C. A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells. J. Immunol. Methods 267, 157–163 (2002).
Bracher, M., Gould, H. J., Sutton, B. J., Dombrowicz, D. & Karagiannis, S. N. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J. Immunol. Methods 323, 160–171 (2007).
Oberst, M. D. et al. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs 6, 1571–1584 (2014).
Yamashita, M. et al. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Sci. Rep. 6, 19772 (2016).

Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity

推荐阅读